




AMENDMENTS TO THE CLAIMS

*NE 1
1/2/15/07*
This listing of claims will replace all prior versions and listings of claims in the application.

Listing Of Claims

1-108. (canceled)

~~109.~~ (currently amended) A compound consists of a formula selected from the group consisting of the formula



wherein




R₂, R₃, R₄, and R₅ are each independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, amino, thio, cyano, nitro, and a carbonyl group, each substituted or unsubstituted;

R₁₄ is selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, a substituted or unsubstituted $-C(O)C_{1-6}\text{alkyl}$, acetyl and BOC heteroaryloxy, arylalkyl, heteroarylalkyl, amino, ~~and a carbonyl group, each substituted or unsubstituted or~~ R₁₄ is a substituent that is convertible *in vivo* to hydrogen;




M is selected from the group consisting of trifluoroacetyl (-C(O)-CF₃), -NH-P(O)OH-CH₃, sulfonamides (-SO₂NH₂), hydroxysulfonamides (-SO₂NHOH), thiols (-SH), and carbonyl groups having the formula -C(O)-R₁₃ wherein R₁₃ is hydroxylamino, hydroxyl, amino, alkylamino, and an alkoxy group, each substituted or unsubstituted; and

L is a substituent providing between 0-10 2-10 atoms separation between the M substituent and the remainder of the compound, wherein the 2-10 atoms are all carbon atoms.

✓ 110. (previously presented) The compound according to claim 109, wherein the compound consists of a formula selected from the group consisting of



3 111. (previously presented) The compound according to claim 109, wherein the compound consists of a formula selected from the group consisting of



4 112. (currently amended) The compound according to claim 109, wherein R₁₄ is hydrogen, selected from the group consisting of hydrogen and a substituent that is convertible *in vivo* to hydrogen.

5 113. (previously presented) The compound according to claim 109, wherein R₁₄ is a substituted or unsubstituted C₁₋₆ alkyl.


6 114. (previously presented) The compound according to claim 109, wherein R₁₄ is a substituted or unsubstituted -C(O)C₁₋₆ alkyl.

7 115. (previously presented) The compound according to claim 109, wherein R₁₄ is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, acetyl, and BOC.

8 116. (previously presented) The compound according to claim 109, wherein at least one of R₂, R₃, R₄, or R₅ is fluoro.


117. (canceled)

9 118. (previously presented) The compound according to claim 109, wherein M is selected from the group consisting of:




10 119. (previously presented) The compound according to claim 109, wherein M is a hydroxamic acid moiety.

11 120. (previously presented) The compound according to claim 109, wherein -L-M is



12 121. (currently amended) A compound of a formula selected from the group consisting of the formula:



wherein




R₂, R₃, R₄, and R₅ are each independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, cyano and nitro, each substituted or unsubstituted;

62
 R_{14} is selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, a substituted or unsubstituted $-C(O)C_{1-6}\text{alkyl}$, acetyl and BOC heteroaryloxy, arylalkyl, heteroarylalkyl, amino, and a carbonyl group, each substituted or unsubstituted, or R_{14} is a substituent that is convertible *in vivo* to hydrogen;




M is selected from the group consisting of trifluoroacetyl ($-C(O)-CF_3$), $-\text{NH-P(O)(OH)-CH}_3$, sulfonamides ($-\text{SO}_2\text{NH}_2$), hydroxysulfonamides ($-\text{SO}_2\text{NHOH}$), thiols ($-\text{SH}$), and carbonyl groups having the formula $-C(O)-R_{13}$ wherein R_{13} is hydroxylamino, hydroxyl, amino, alkylamino, and an alkoxy group, each substituted or unsubstituted; and

L is a substituent providing between 2-10 atoms separation between the M substituent and the remainder of the compound, wherein the 2-10 atoms are all carbon atoms.

13 **122.** (previously presented) The compound according to claim 121, wherein the compound consists of a formula selected from the group consisting of



14 **125.** (previously presented) The compound according to claim 121, wherein the compound consists of a formula selected from the group consisting of



15 **124.** (currently amended) The compound according to claim 121, wherein R_{14} is hydrogen, selected from the group consisting of hydrogen and a substituent that is convertible *in vivo* to hydrogen.

16 125. (previously presented) The compound according to claim 121, wherein R₁₄ is a substituted or unsubstituted C₁₋₆ alkyl.


17 126. (previously presented) The compound according to claim 121, wherein R₁₄ is a substituted or unsubstituted -C(O)C₁₋₆ alkyl.

18 127. (previously presented) The compound according to claim 121, wherein R₁₄ is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, acetyl, and BOC.

19 128. (previously presented) The compound according to claim 121, wherein at least one of R₂, R₃, R₄, or R₅ is fluoro.


129. (canceled)

20 130. (previously presented) The compound according to claim 121, wherein M is selected from the group consisting of:






21 131. (previously presented) The compound according to claim 121, wherein M is a hydroxamic acid moiety.

22 132. (previously presented) The compound according to claim 121, wherein -L-M is



23 133. (currently amended) A compound of a formula selected from the group consisting of the formula:




wherein

R₂, R₃, R₄, and R₅ are each independently selected from the group consisting of hydrogen, halo, (C₁₋₁₀)alkyl, (C₁₋₁₀)alkoxy, (C₅₋₁₂)aryl, (C₅₋₁₂)heteroaryl, cyano, and nitro, each substituted or unsubstituted;

R₁₄ is selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, a substituted or unsubstituted -C(O)C₁₋₆alkyl, acetyl and BOC heteroaryloxy, arylalkyl, heteroarylalkyl, amino, and a carbonyl group, each substituted or unsubstituted, or R₁₄ is a substituent that is convertible *in vivo* to hydrogen;




M is selected from the group consisting of






and

L is selected from the group consisting of (E) isomer of -CH=CH-, (Z) isomer or -CH=CH-, and mixtures of (E) and (Z) isomers of -CH=CH-.

24 134. (previously presented) The compound according to claim 133, wherein the compound consists of a formula selected from the group consisting of



25 135. (previously presented) The compound according to claim 133, wherein the compound consists of a formula selected from the group consisting of



26 136. (currently amended) The compound according to claim 133, wherein R14 is hydrogen.
~~selected from the group consisting of hydrogen and a substituent that is convertible *in vivo* to hydrogen.~~

27 137. (previously presented) The compound according to claim 133, wherein R14 is a substituted or unsubstituted C₁₋₆ alkyl.

28 138. (previously presented) The compound according to claim 133, wherein R14 is a substituted or unsubstituted -C(O)C₁₋₆ alkyl.


29 139. (previously presented) The compound according to claim 133, wherein R14 is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, acetyl, and BOC.

30 140. (previously presented) The compound according to claim 133, wherein at least one of R₂, R₃, R₄, or R₅ is fluoro.


141-142. (canceled)

31 143. (previously presented) The compound according to claim 133, wherein M is a hydroxamic acid moiety.


32 144. (previously presented) The compound according to claim 133, wherein -L-M is




33 145. (previously presented) The compound according to claim 109, wherein M is




34 146. (previously presented) The compound according to claim 109, wherein M is




35 147. (previously presented) The compound according to claim 109, wherein M is




36 148. (previously presented) The compound according to claim 109, wherein M is




37 149. (previously presented) The compound according to claim 109, wherein M is



38 150. (previously presented) The compound according to claim 109, wherein M is




39 151. (previously presented) The compound according to claim 109, wherein M is




40 152. (previously presented) The compound according to claim 109, wherein M is




41 153. (previously presented) The compound according to claim 109, wherein M is




42 154. (previously presented) The compound according to claim 109, wherein M is




43 155. (previously presented) The compound according to claim 121, wherein M is




44 156. (previously presented) The compound according to claim 121, wherein M is




45 157. (previously presented) The compound according to claim 121, wherein M is




46 158. (previously presented) The compound according to claim 121, wherein M is




47 159. (previously presented) The compound according to claim 121, wherein M is



48 160. (previously presented) The compound according to claim 121, wherein M is




49 161. (previously presented) The compound according to claim 121, wherein M is




50 162. (previously presented) The compound according to claim 121, wherein M is




51 163. (previously presented) The compound according to claim 121, wherein M is




52 164. (previously presented) The compound according to claim 121, wherein M is




53 165. (previously presented) The compound according to claim 121, wherein M is




54 166. (previously presented) The compound according to claim 133, wherein M is




55 167. (previously presented) The compound according to claim 133, wherein M is




56 168. (previously presented) The compound according to claim 133, wherein M is



57 169. (previously presented) The compound according to claim 133, wherein M is




58 170. (previously presented) The compound according to claim 133, wherein M is




59 171. (previously presented) The compound according to claim 133, wherein M is



60 172. (previously presented) The compound according to claim 133, wherein M is




61 173. (previously presented) The compound according to claim 133, wherein M is



174-175. (canceled)

62 176. (previously presented) The compound according to claim 109, wherein -L-M is



63 177. (previously presented) The compound according to claim 121, wherein -L-M is

